Marengo Tx appoints Saso Cemerski as head of immunology

Cambridge, USA-based clinical-stage biotech Marengo Therapeutics has announced two important milestones reflecting the advancement of its TriSTAR platform: the appointment of Saso Cemerski as senior vice president, head of immunology; and nomination of the first development candidate under its TriSTAR strategic collaboration with Ipsen (Euronext: IPN).

Building on this momentum, Marengo is strengthening its scientific leadership with the appointment of Dr Cemerski, an industry-leading expert in T-cell engager discovery and immune-cell activation Dr Cemerski will lead immunology research across Marengo’s clinical and pre-clinical portfolio, help shape the company’s scientific strategy and accelerate expansion of its pipeline of precision Vβ-directed T-cell therapies.